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Abstract
© 2018 L. S. Usmanova et al. Inhalation administration is a promising alternative to the invasive
drug delivery methods. The particle size required for ideal drug aerosol preparation is between 1
and  3  μm.  The  application  of  microspherical  particles  of  solid  dispersions  enhances
bioavailability of poorly soluble drugs due to the solubilization. In the present work, the spray
drying  process  of  the  production  of  microspherical  particles  of  solid  dispersions  of
polyvinylpyrrolidone K29-32 with model hydrophobic drug, phenacetin, was optimized using the
results of DSC, PXRD, and viscometry. The diameter of the obtained particles is within 1-3 μm
range. The Gibbs energy of dissolution in water was shown to be negative for the mixture with
polymer/phenacetin mass ratio 5: 1. We have demonstrated that the optimal size distribution for
the inhalation administration is obtained for microspherical particles produced using spray caps
with 7.0 μm hole size. The dissolution rates of phenacetin from the produced microspherical
particles were faster than that of drug powder. As evidenced by powder X-ray diffraction data,
phenacetin  stayed  in  amorphous  state  for  4  months  in  microspherical  particles  of  solid
dispersions. According to the obtained results, strategic application of the spray drying process
could  be  beneficial  for  the  improvement  of  the  pharmaceutical  properties  of  model  drug,
phenacetin.
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